Payment overview · 2025
General Payments
$600.20
31 reported records · 10 companies
Healthcare provider profile · identity verified
Bhupendra Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUSQUEHANNA, PA · NPI 1649216466
Verified facts
What the public records show
CMS Open Payments records show Bhupendra Patel, MD received $600.20 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.65 | 27.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.90 | 23.0% | 7 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $67.69 | 11.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.34 | 11.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.31 | 9.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.92 | 5.5% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.19 | 3.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.73 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.37 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.10 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $600.20 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.02 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $67.69 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $67.34 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.78 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.78 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.34 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $55.31 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 248 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
248 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 172 |
| Alprazolam | Alprazolam | 476 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 76 |
| Furosemide | Furosemide | 369 | 90 |
| Potassium Chloride | Potassium Chloride | 337 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 320 | 92 |
| Omeprazole | Omeprazole | 309 | 83 |
| Simvastatin | Simvastatin | 251 | 70 |
| Eliquis | Apixaban | 248 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 61 |
| Lisinopril | Lisinopril | 239 | 79 |
| Metformin Hcl | Metformin Hcl | 236 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 57 |
| Gabapentin | Gabapentin | 200 | 39 |
| Meloxicam | Meloxicam | 196 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 194 | 42 |
| Glipizide | Glipizide | 186 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 51 |
| Famotidine | Famotidine | 161 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 33 |
| Losartan Potassium | Losartan Potassium | 138 | 29 |
| Clonidine Hcl | Clonidine Hcl | 135 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 25 |
| Nifedipine Er | Nifedipine | 126 | 33 |
| Tramadol Hcl | Tramadol Hcl | 120 | 32 |
| Sertraline Hcl | Sertraline Hcl | 119 | 24 |
| Temazepam | Temazepam | 119 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 113 | 33 |
| Donepezil Hcl | Donepezil Hcl | 107 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | suppressed |
| Xarelto | Rivaroxaban | 95 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 94 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 90 | suppressed |
| Cephalexin | Cephalexin | 88 | 66 |
| Allopurinol | Allopurinol | 84 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 74 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 81 | 22 |
| Montelukast Sodium | Montelukast Sodium | 80 | 18 |
| Diazepam | Diazepam | 75 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 27 |
| Lorazepam | Lorazepam | 70 | 15 |
| Ramipril | Ramipril | 70 | 20 |
| Spironolactone | Spironolactone | 67 | 14 |
| Enulose | Lactulose | 66 | suppressed |
| Atenolol | Atenolol | 65 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 21 |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 39 |
| Prednisone | Prednisone | 58 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 44 |
| Finasteride | Finasteride | 55 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Naproxen | Naproxen | 54 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | 16 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 15 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Ozempic | Semaglutide | 39 | 12 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 37 | 24 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Invokana | Canagliflozin | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 31 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Mupirocin | Mupirocin | 31 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 24 |
| Carvedilol | Carvedilol | 28 | 11 |
| Digoxin | Digoxin | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 24 |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | 13 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Metolazone | Metolazone | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $600.20 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, FARXIGA, ONPATTRO, Ohtuvayre, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Veozah, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error